{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:26:19Z","timestamp":1792027579929,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA87969"],"award-info":[{"award-number":["P01 CA87969"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA176726"],"award-info":[{"award-number":["U01 CA176726"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oral contraceptives (OCs) have been associated with long-term lower endometrial cancer risk; relatively little is known about associations with more recent OC formulations and associations with longer-term risk. A total of 107,069 women from the Nurses\u2019 Health Study II recalled OC use from age 13 to baseline (1989); biennial questionnaires updated data on OC use until 2009. OCs were classified by estrogen and progestin type, dose, and potency based on reported brand. 864 incident endometrial cancer cases were identified through 2017. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals [95% CI] for the association of OC use with endometrial cancer risk. OC use was associated with lower endometrial cancer risk (ever use, HR 0.77 [95% CI 0.65\u20130.91]; &gt;10 years of use, 0.43 [0.32\u20130.58] vs. never OC use). Inverse associations for duration were evident regardless of time since last use. Longer durations (&gt;\u20095\u00a0years) of ethinyl estradiol (0.52 [0.41\u20130.67]) and second-generation progestins (0.43 [0.30\u20130.61]), both versus never use, were more strongly associated with lower risk than mestranol (0.66 [0.50\u20130.88], p-het\u2009=\u20090.01) and first-generation progestins (0.62 [0.49\u20130.78], p-het\u2009=\u20090.03). Inverse associations were generally observed for cross-classified cumulative average estrogen and progestin dose and potency (&lt;\u2009vs. \u2265 median; ever use vs. never OC use), with the exception of high estrogen and low progestin dose. OCs were associated with lower endometrial cancer risk, independent of time since last use. Use of ethinyl estradiol and second-generation progestins were more strongly inversely associated with risk compared with older formulations.<\/jats:p>","DOI":"10.1007\/s10654-020-00705-5","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T05:03:52Z","timestamp":1608181432000},"page":"827-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947\u20131964: The Nurses\u2019 Health Study II, a prospective cohort study"],"prefix":"10.1007","volume":"36","author":[{"given":"Norah A.","family":"Burchardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Shafrir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Kaaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley S.","family":"Tworoger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e T.","family":"Fortner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"705_CR1","unstructured":"Daniels K, Daugherty J, Jones J, Mosher W. Current contraceptive use and variation by selected characteristics among women aged 15\u201344: United States, 2011\u20132013. Hyattsville, MD; 2015."},{"key":"705_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/s-0036-1572546","volume":"34","author":"A Golobof","year":"2016","unstructured":"Golobof A, Kiley J. The current status of oral contraceptives: progress and recent innovations. Semin Reprod Med. 2016;34:145\u201351.","journal-title":"Semin Reprod Med"},{"issue":"23","key":"705_CR3","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","volume":"377","author":"L M\u00f8rch","year":"2017","unstructured":"M\u00f8rch L, Skovlund C, Hannaford P, Iversen L, Fielding S, Lidegaard \u00d8. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228\u201339.","journal-title":"N Engl J Med"},{"issue":"6","key":"705_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.contraception.2012.05.003","volume":"86","author":"K Hall","year":"2012","unstructured":"Hall K, Trussell J, Schwarz E. Progestin-only contraceptive pill use among women in the United States. Contraception. 2012;86(6):653\u20138.","journal-title":"Contraception"},{"key":"705_CR5","unstructured":"Institute of Medicine Committee on the Relationship Between Oral Contraceptives and Breast Cancer. Appendix C: The evolving formulations of oral contraceptives. In: Press NA, editor. Oral Contraceptives & Breast Cancer. Washington (DC); 1991."},{"issue":"1","key":"705_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2105\/AJPH.81.1.90","volume":"81","author":"B Gerstman","year":"1991","unstructured":"Gerstman B, Gross T, Kennedy D, Bennett R, Tomita D, Stadel B. Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health. 1991;81(1):90\u20136.","journal-title":"Am J Public Health"},{"issue":"1","key":"705_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/oxfordjournals.bmb.a072592","volume":"49","author":"M Thorogood","year":"1993","unstructured":"Thorogood M, Villard-Mackintosh L. Combined oral contraceptives: risks and benefits. Br Med Bull. 1993;49(1):124\u201339.","journal-title":"Br Med Bull"},{"key":"705_CR8","volume-title":"Yen & Jaffe\u2019s reproductive endocrinology: physiology, pathophysiology, and clinical management, 8e","author":"C Schreiber","year":"2019","unstructured":"Schreiber C, Barnhart K. Contraception. In: Strauss JFBR, editor. Yen & Jaffe\u2019s reproductive endocrinology: physiology, pathophysiology, and clinical management, 8e. Philadelphia: Elsevier Inc.; 2019."},{"issue":"4","key":"705_CR9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/GRF.0b013e318159c06a","volume":"50","author":"J Kiley","year":"2007","unstructured":"Kiley J, Hammond C. Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol. 2007;50(4):868\u201377.","journal-title":"Clin Obstet Gynecol"},{"key":"705_CR10","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Combined estrogen\u2013progestogen contraceptives. Pharmaceuticals. Lyon (France): International Agency for Research on Cancer (IARC); 2012."},{"issue":"S1","key":"705_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/09513590701585003","volume":"23","author":"J Pasqualini","year":"2007","unstructured":"Pasqualini J. Progestins and breast cancer. Gynecol Endocrinol. 2007;23(S1):32\u201341.","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"705_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/humupd\/dmq022","volume":"16","author":"D Cibula","year":"2010","unstructured":"Cibula D, Gompel A, Mueck A, Vecchia CL, Hannaford P, Skouby S, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16(6):631\u201350.","journal-title":"Hum Reprod Update"},{"key":"705_CR13","volume-title":"A clinical guide for contraception","author":"L Speroff","year":"2011","unstructured":"Speroff L, Darney PD. Oral contraception. In: Speroff L, Darney PD, editors. A clinical guide for contraception. Philadelphia: Lippincott Williams and Wilkins; 2011."},{"key":"705_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(15)00212-0","volume":"16","author":"Collaborative Group on Epidemiological Studies on Endometrial Cancer","year":"2015","unstructured":"Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061\u201370.","journal-title":"Lancet Oncol"},{"issue":"3","key":"705_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.bjc.6603260","volume":"95","author":"M Vessey","year":"2006","unstructured":"Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968\u20132004. Br J Cancer. 2006;95(3):385\u20139.","journal-title":"Br J Cancer"},{"issue":"7621","key":"705_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/bmj.39289.649410.55","volume":"335","author":"P Hannaford","year":"2007","unstructured":"Hannaford P, Selvaraj S, Elliott A, Angus V, Iversen L, Lee A. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner\u2019s oral contraception study. BMJ. 2007;335(7621):651.","journal-title":"BMJ"},{"issue":"580","key":"705_CR17","first-page":"e1","volume":"216","author":"L Iversen","year":"2017","unstructured":"Iversen L, Sivasubramaniam S, Lee A, Fielding S, Hannaford P. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners\u2019 Oral Contraceptive Study. Am J Obstet Gynecol. 2017;216(580):e1\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"705_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaoncol.2017.4942","volume":"4","author":"K Michels","year":"2018","unstructured":"Michels K, Pfeiffer R, Brinton L, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast and colorectal cancers. JAMA Oncol. 2018;4(4):516\u201321.","journal-title":"JAMA Oncol"},{"issue":"3","key":"705_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.contraception.2020.06.008","volume":"102","author":"L Iversen","year":"2020","unstructured":"Iversen L, Fielding S, Lidegaard O, Hannaford P. Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: a retrospective cohort study of Danish women. Contraception. 2020;102(3):152\u2013158.","journal-title":"Contraception."},{"key":"705_CR20","unstructured":"American Cancer Society. Cancer Statistics Center. Uterine corpus. https:\/\/cancerstatisticscenter.cancer.org\/?_ga=2.88103257.395496001.1605523510-1088197459.1605523510#!\/cancer-site\/Uterine%20corpus. Accessed 20 Nov 2020."},{"issue":"5","key":"705_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nrc1608","volume":"5","author":"G Colditz","year":"2005","unstructured":"Colditz G, Hankinson S. The Nurses\u2019 Health Study: lifestyle and health among women. Nat Rev Cancer. 2005;5(5):388\u201396.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"705_CR22","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.2105\/AJPH.2016.303338","volume":"106","author":"Y Bao","year":"2016","unstructured":"Bao Y, Bertoia M, Lenart E, Stampfer M, Willett W, Speizer F, et al. Origin, methods, and evolution of the three Nurses\u2019 Health Studies. Am J Public Health. 2016;106(9):1573\u201381.","journal-title":"Am J Public Health"},{"issue":"5","key":"705_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10552-017-0876-0","volume":"28","author":"A Shafrir","year":"2017","unstructured":"Shafrir A, Schock H, Poole E, Terry K, Tamimi R, Hankinson S, et al. A prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964. Cancer Causes Control. 2017;28(5):371\u201383.","journal-title":"Cancer Causes Control"},{"key":"705_CR24","unstructured":"Davtyan C. Four generations of progestins in oral contraceptives. Proceedings of UCLA Healthcare UCLA Department of Medicine. 2012;16."},{"key":"705_CR25","volume-title":"Managing contraceptive pill patients","author":"R Dickey","year":"1987","unstructured":"Dickey R. Managing contraceptive pill patients. 5 ed. Durant: Creative Informatics; 1987.","edition":"5"},{"key":"705_CR26","volume-title":"Managing contraceptive pill patients","author":"R Dickey","year":"2002","unstructured":"Dickey R. Managing contraceptive pill patients. 11 ed. Dallas: EMIS, Inc; 2002.","edition":"11"},{"key":"705_CR27","volume-title":"Managing contraceptive pill\/drug patients","author":"R Dickey","year":"2010","unstructured":"Dickey R. Managing contraceptive pill\/drug patients. 14 ed. New Orleans: EMIS, Inc; 2010.","edition":"14"},{"key":"705_CR28","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/sim.6793","volume":"35","author":"M Wang","year":"2016","unstructured":"Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan A, et al. Statistical methods for studying disease subtype heterogeneity. Statist Med. 2016;35:782\u2013800.","journal-title":"Statist Med"},{"key":"705_CR29","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"J Higgins","year":"2002","unstructured":"Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"705_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/sim.4780080504","volume":"8","author":"S Durrleman","year":"1989","unstructured":"Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551\u201361.","journal-title":"Stat Med"},{"key":"705_CR31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ijc.25050","volume":"127","author":"L Dossus","year":"2010","unstructured":"Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;127:442\u201351.","journal-title":"Int J Cancer"},{"issue":"6","key":"705_CR32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1001\/jama.1987.03390060086029","volume":"257","author":"The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development","year":"1987","unstructured":"The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA. 1987;257(6):796\u2013800.","journal-title":"JAMA"},{"key":"705_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ijc.2910540214","volume":"54","author":"J Stanford","year":"1993","unstructured":"Stanford J, Brinton L, Berman M, Mortel R, Twiggs L, Barrett R, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer. 1993;54:243\u20138.","journal-title":"Int J Cancer"},{"key":"705_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF01830241","volume":"5","author":"L Voigt","year":"1994","unstructured":"Voigt L, Deng Q, Weiss N. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control. 1994;5:227\u201333.","journal-title":"Cancer Causes Control"},{"key":"705_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1023\/A:1008945721786","volume":"10","author":"E Weiderpass","year":"1999","unstructured":"Weiderpass E, Adami H, Baron J, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10:277\u201384.","journal-title":"Cancer Causes Control"},{"key":"705_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/bjc.1988.44","volume":"57","author":"T Key","year":"1988","unstructured":"Key T, Pike M. The dose-effect relationship between \u2018unopposed\u2019 oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57:205\u201312.","journal-title":"Br J Cancer"},{"key":"705_CR37","first-page":"3232","volume":"42","author":"B Henderson","year":"1982","unstructured":"Henderson B, Ross R, Pike M, Casagrande J. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982;42:3232\u20139.","journal-title":"Cancer Res"},{"key":"705_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/jnci\/83.6.405","volume":"83","author":"E Gurpide","year":"1991","unstructured":"Gurpide E. Endometrial cancer: biochemical and clinical correlates. J Natl Cancer Inst. 1991;83:405\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"705_CR39","first-page":"502","volume":"18","author":"J Graham","year":"1997","unstructured":"Graham J, Clarke C. Physiological action of progesterone in target tissues. Endocrinol Rev. 1997;18:502\u2013219.","journal-title":"Endocrinol Rev"},{"key":"705_CR40","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1136\/bmj.2.6048.1354","volume":"2","author":"J Kjeld","year":"1976","unstructured":"Kjeld J, Puah C, Joplin G. Changed levels of endogenous sex steroids in women on oral contraceptives. BMJ. 1976;2:1354\u20136.","journal-title":"BMJ"},{"issue":"6","key":"705_CR41","first-page":"266","volume":"76","author":"M Mall-Haefeli","year":"1983","unstructured":"Mall-Haefeli M, Werner-Zodrow I, Huber P, Darragh A, Lambe R. Effects of various combined oral contraceptives on sex steroids, gonadotropins and SHBG. Ir Med J. 1983;76(6):266\u20137.","journal-title":"Ir Med J"},{"issue":"6","key":"705_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0010-7824(83)90023-9","volume":"27","author":"U Gaspard","year":"1983","unstructured":"Gaspard U, Romus M, Gillian D, Duvivier J, Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception. 1983;27(6):577\u201390.","journal-title":"Contraception"},{"issue":"1","key":"705_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/humupd\/dmt038","volume":"20","author":"Y Zimmerman","year":"2014","unstructured":"Zimmerman Y, Eijkemans M, Bennink HC, Blankenstein M, Fauser B. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):76\u2013105.","journal-title":"Hum Reprod Update"},{"key":"705_CR44","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(13)70301-2","volume":"14","author":"Endogenous Hormones and Breast Cancer Collaborative Group","year":"2013","unstructured":"Endogenous Hormones and Breast Cancer Collaborative Group. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol. 2013;14:1009\u201319.","journal-title":"Lancet Oncol"},{"issue":"7","key":"705_CR45","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1054\/bjoc.2001.1704","volume":"84","author":"A Zeleniuch-Jacquotte","year":"2001","unstructured":"Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig K, Shore R, Kim M, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer. 2001;84(7):975\u201381.","journal-title":"Br J Cancer"},{"key":"705_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ijc.11529","volume":"108","author":"A Lukanova","year":"2004","unstructured":"Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004;108:425\u201332.","journal-title":"Int J Cancer"},{"key":"705_CR47","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1677\/ERC-07-0064","volume":"15","author":"N Allen","year":"2008","unstructured":"Allen N, Key T, Dossus L, Rinaldi S, Cust A, Lukanova A, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2008;15:485\u201397.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"705_CR48","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/1055-9965.EPI-07-2686","volume":"17","author":"M Gunter","year":"2008","unstructured":"Gunter M, Hoover D, Yu H, Wassertheil-Smoller S, Manson J, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomark Prev. 2008;17(4):921\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"705_CR49","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/ijc.2910490612","volume":"49","author":"K Rosenblatt","year":"1991","unstructured":"Rosenblatt K, Thomas D. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 1991;49:870\u20134.","journal-title":"Int J Cancer"},{"key":"705_CR50","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ygyno.2006.03.046","volume":"103","author":"G Maxwell","year":"2006","unstructured":"Maxwell G, Schildkraut J, Calingaert B, Risinger J, Dainty L, Marchbanks P, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103:535\u201340.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"705_CR51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.path.2019.01.003","volume":"12","author":"W Mallinger","year":"2019","unstructured":"Mallinger W, Quick C. Benign and premalignant lesions of the endometrium. Surg Pathol Clin. 2019;12(2):315\u201328.","journal-title":"Surg Pathol Clin"},{"issue":"20","key":"705_CR52","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","volume":"31","author":"V Setiawan","year":"2013","unstructured":"Setiawan V, Yang H, Pike M, McCann S, Yu H, Xiang Y, et al. Type I and II endometrial cancers: Have they different risk factors? J Clin Oncol. 2013;31(20):2607\u201318.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-020-00705-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10654-020-00705-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-020-00705-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T05:36:43Z","timestamp":1698471403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10654-020-00705-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1007\/s10654-020-00705-5","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"NAB, RK, and RTF have nothing to disclose. ALS reports grants from the NIHCD\/NIH and funding support from the Marriott Family Foundations. SST reports grants from NCI\/NIH during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The study was approved by the institutional review boards (IRBs) of the Brigham and Women\u2019s Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required. The IRBs allowed participants\u2019 completion of questionnaires to be considered as implied consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"RTF affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency declaration"}}]}}